A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Effects of Reducing Body Fat by Daily Ingestion of Shiikuwasha (Citrus depressa Hayata) Juice
- Conditions
- Healthy adults
- Registration Number
- JPRN-UMIN000028820
- Lead Sponsor
- Hokkaido Information University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
1. Subjects who are under physician's advice, treatment and/or medication for obese, hyperlipidemia and diabetes. 2. Subjects who regularly take anticoagulants (warfarin, etc.) or antiaggregant (aspirin, clopidgrel, ticlopidine, cilostazol, etc.) 3. Subjects whose BMI is >=30 kg/m2. 4. Subjects with familial hypercholesterolemia. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 6. Pacemaker or defibrillator users. 7. Subjects with major surgical history relevant to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 8. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 9. Subjects with severe anemia. 10. Pre- or post-menopausal women complaining obvious physical changes. 11. Subjects who are at risk of having allergic reactions to drugs or foods based on especially citrus fruits. 12. Subjects who regularly take medicine, functional foods, and/or supplements which would affect BW and BFP. 13. Subjects who regularly take medicine, functional foods, and/or supplements which would affect blood lipid levels. 14. Subjects who regularly take medicine, functional foods and/or supplements which would affect glucose metabolism. 15. Heavy smokers, alcohol addicts or subjects with the eating disordered lifestyle. 16. Subjects who donated either 400ml whole blood within 16 weeks (women) /12 weeks (men) or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to the current study. 17. Pregnant or lactating women or women expect to be pregnant during this study. 18. Subjects who currently participate in other clinical trials or participated within the last 4 weeks prior to the current study. 19. Any other medical and/ or health reasons unfavorable to participation into the current study judged by the principal investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Abdominal visceral fat area after 4, 8 and 12 weeks of ingestion
- Secondary Outcome Measures
Name Time Method Abdominal total fat area, abdominal subcutaneous fat area, body weight, BFP, BMI, waist circumference, hip circumference, waist-hip ratio, TC, LDL-C, HDL-C, TG, LDL-C/HDL-C, non-HDL, fasting blood glucose levels, HbA1c, insulin, HOMA-IR, adiponectin and leptin